<DOC>
	<DOCNO>NCT00219362</DOCNO>
	<brief_summary>Prior pilot study show four monthly injection ALVAC-HIV ( vCP1433 ) immunogenic 60 % HIV-infected patient boost effect obtain 1 2 injection follow plateau decrease response prior interrupt therapy . The goal present study look improve vaccination schedule term strength duration HIV-specific immunity induce HIV-recombinant canary pox vector ALVAC-HIV ( vCP1452 ) test strategy immunization involve first series two versus three monthly injection follow boost three month later .</brief_summary>
	<brief_title>Immunogenicity Safety 2 Schedules ALVAC-HIV vCP1452 Chronically HIV-Infected Patients</brief_title>
	<detailed_description>Manon 02 phase II , multicentre , randomize , placebo-controlled study 3 arm comprise 2 step : Step I : Immunization phase W0 W24 , HAART The immunization administer intramuscular injection : Arm A : one injection vCP1452 W0 , W4 , W8 W20 + HAART , total 4 injection Arm B : one injection vCP1452 W4 , W8 W20 + HAART , total 3 injection Arm C : one injection placebo W0 , W4 , W8 W20 + HAART , total 4 injection W4 , W8 W20 + HAART , total 3 injection Step II : Post immunization phase W24 W48 , HAART Discontinuation antiretroviral therapy ( ARV ) W24 W48 : The ARV treatment interruption propose W24 , 4 week last immunization , patient complete immunization phase CD4 cell count &gt; 350 cells/mm3 HIV plasma RNA &lt; 400 cp/ml . In order able evaluate capacity immune response reduce viral replication , period 16 week interruption recommend W24 W40 . Resumption antiretroviral therapy : From W24 W40 : During 16 week period , case decline CD4 cell count 250 cells/mm3 loss CD4 great 50 % baseline value , HAART restart . From W40 W48 : HAART reintroduce HIV-1 RNA level &gt; 50 000 cp/ml 2 consecutive measurement two week interval even CD4 count 250 cells/mm3 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Documented HIV infection potent antiretroviral therapy 6 month entry CD4+ count &gt; 350 cells/mm3 least 1 year plasma HIV RNA &lt; 400 cp/ml least last 6 month Contraception need woman Antiretroviral therapy start CD4 cell count &gt; 400/mm3 Patients treated time primary HIV infection Patient past AIDS defining event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>